Publications by authors named "Jennifer Pulini"

Claim this Profile
P
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, Michele Guida, Caroline Gaudy-Marqueste, Jennifer Pulini

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Jennifer Pulini

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma.
Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E Janik

Gynecol Oncol Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, Catherine S Diefenbach, Patrick Johnston, Jennifer Pulini

Blood· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis